The company will showcase its drum-filling technology among other products and services at the upcoming ACHEMA 2018 event in Frankfurt, Germany.

The agency updated its list of recommended influenza virus strains that manufacturers should include in vaccines for the autumn 2018 season.

After a review of public comments, USP will not move forward with nomenclature proposal without further FDA collaboration.

The company received a complete response letter from FDA in response to the biologics license application for a proposed trastuzumab biosimilar.

The company’s investment in new laboratory equipment and personnel will strengthen its cell line development services.

The company doubled capacity for laboratory services at its facility in Itasca, IL.

The company showcased newer products and equipment for cell culture laboratories at Analytica 2018 in Munich, Germany.

Proteus Digital Health is collaborating on a pipeline of digital, oral solid-dosage drugs for various therapies, including cardiovascular and oncology drugs, based on its first NDA, which used ingestible sensors in an antipsychotic treatment.

The company will add a new $5-million drug development center of excellence at its facility and headquarters in Somerset, NJ.

EMA and its new host country have finalized the terms of the agency’s relocation to Amsterdam.

Scientists at Washington University School of Medicine in St. Louis have developed a new method that could help increase the long-term effectiveness of gene therapy.

Research from Gladstone Institutes suggests that transplanting genetically altered interneurons could improve cognitive function for Alzheimer’s disease.

Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.

Thermo Fisher Scientific invests $50 Million to expand biologics drug development and manufacturing capabilities in St. Louis, MO.

A federal judge from the Eastern District of Arkansas entered into a consent decree with Cantrell Drug Company.

The new platform is expected to speed up cell line development.

The agency has released new guidance on the development of new medication-assisted treatments for opioid dependence.

LNC Therapeutics has appointed a new CEO and is strengthening its R&D for gut microbiome-based drugs.

FDA’s Center for Drug Evaluation and Research has published its second annual report on key safety programs and activities.

The contract renewal allows AMRI to continue to provide medicinal chemistry and ADME services for advancing drug discovery programs in neurotherapeutics.

The expanded Laboratory Testing Division, located in Cranbury, NJ, will expand the company’s testing services in the United States.

The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.

Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.

The new document answers questions regarding implementation of the ICH Q7 guidance on GMPs for APIs.

The company unveiled three new products to support single-use biomanufacturing and won an award for best technological innovation at INTERPHEX 2018.

Johnson & Johnson’s Janssen partners with Bristol-Myers Squibb to advance next-generation therapies for cardiovascular diseases.

The agency has granted breakthrough therapy designation to Roche’s hemophilia therapy for treating hemophilia A in patients without factor VIII inhibitors.

INTERPHEX presents advances in pharmaceutical container filling, robotic handling, and serialization.